Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, announced the acceptance of six abstracts for presentation at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop in Copenhagen. The presentations focus on deucrictibant, an oral bradykinin B2 receptor antagonist for treating hereditary angioedema (HAE) attacks. Two oral presentations and four poster presentations will cover topics including:
1. Long-term safety and efficacy of deucrictibant for HAE prophylaxis
2. Long-term efficacy and safety in treating HAE attacks
3. Results from the CHAPTER-1 Phase 2 trial
4. Impact on health-related quality of life
5. Comparison with standard of care treatments
6. Design of the RAPIDe-3 Phase 3 trial
Presentation materials will be available on the Pharvaris website. The company will also make a donation to the Marcus Maurer Fellowship Program through GA2LEN in memory of Prof. Marcus Maurer.
Pharvaris (Nasdaq: PHVS), una compagnia biofarmaceutica in fase avanzata, ha annunciato l'accettazione di sei abstract per la presentazione al Global Angioedema Forum 2024 – HAEi Global Leadership Workshop a Copenaghen. Le presentazioni si concentrano su deucrictibant, un antagonista orale del recettore bradichinina B2 per il trattamento degli attacchi di angioedema ereditario (HAE). Due presentazioni orali e quattro presentazioni poster tratteranno argomenti tra cui:
1. Sicurezza ed efficacia a lungo termine di deucrictibant per la profilassi dell'HAE
2. Efficacia e sicurezza a lungo termine nel trattamento degli attacchi di HAE
3. Risultati dalla sperimentazione CHAPTER-1 di fase 2
4. Impatto sulla qualità della vita correlata alla salute
5. Confronto con i trattamenti standard
6. Progetto della sperimentazione RAPIDe-3 di fase 3
I materiali di presentazione saranno disponibili sul sito web di Pharvaris. L'azienda effettuerà anche una donazione al Marcus Maurer Fellowship Program attraverso GA2LEN in memoria del Prof. Marcus Maurer.
Pharvaris (Nasdaq: PHVS), una compañía biofarmacéutica en etapa avanzada, anunció la aceptación de seis resúmenes para su presentación en el Global Angioedema Forum 2024 – HAEi Global Leadership Workshop en Copenhague. Las presentaciones se centran en deucrictibant, un antagonista oral del receptor bradiquinina B2 para tratar los ataques de angioedema hereditario (HAE). Se realizarán dos presentaciones orales y cuatro presentaciones en póster que cubrirán temas como:
1. Seguridad y eficacia a largo plazo de deucrictibant para la profilaxis de HAE
2. Eficacia y seguridad a largo plazo en el tratamiento de ataques de HAE
3. Resultados del ensayo CHAPTER-1 de fase 2
4. Impacto en la calidad de vida relacionada con la salud
5. Comparación con tratamientos estándar
6. Diseño del ensayo RAPIDe-3 de fase 3
Los materiales de presentación estarán disponibles en el sitio web de Pharvaris. La compañía también hará una donación al Programa de Becas Marcus Maurer a través de GA2LEN en memoria del Prof. Marcus Maurer.
Pharvaris (Nasdaq: PHVS)는 후반 단계의 생명공학 회사로, 2024 글로벌 혈관 부종 포럼 - HAEi 글로벌 리더십 워크숍에서 발표를 위한 여섯 개 초록이 수락되었다고 발표했다. 발표는 유전성 혈관부종(HAE) 공격 치료를 위한 경구 브라디키닌 B2 수용체 길항제인 deucrictibant에 초점을 맞춘다. 두 개의 구두 발표와 네 개의 포스터 발표가 포함된 주제는 다음과 같다:
1. HAE 예방을 위한 deucrictibant의 장기 안전성 및 효능
2. HAE 공격 치료 시 장기 효능 및 안전성
3. CHAPTER-1 2상 시험 결과
4. 건강 관련 삶의 질에 미치는 영향
5. 표준 치료와의 비교
6. RAPIDe-3 3상 시험 설계
발표 자료는 Pharvaris 웹사이트에서 확인할 수 있다. 회사는 또한 Marcus Maurer 교수의 기억을 기리기 위해 GA2LEN을 통해 Marcus Maurer Fellowship Program에 기부할 예정이다.
Pharvaris (Nasdaq: PHVS), une entreprise biopharmaceutique en phase avancée, a annoncé l'acceptation de six résumés pour présentation lors du Forum mondial sur l'angio-œdème 2024 – Atelier mondial sur le leadership HAEi à Copenhague. Les présentations portent sur deucrictibant, un antagoniste oral du récepteur B2 de la bradykinine pour le traitement des attaques d'angio-œdème héréditaire (HAE). Deux présentations orales et quatre présentations affichées aborderont des sujets tels que :
1. Sécurité et efficacité à long terme de deucrictibant pour la prophylaxie de l'HAE
2. Efficacité et sécurité à long terme dans le traitement des attaques de l'HAE
3. Résultats de l'essai de phase 2 CHAPTER-1
4. Impact sur la qualité de vie liée à la santé
5. Comparaison avec les traitements standards
6. Conception de l'essai de phase 3 RAPIDe-3
Les matériaux de présentation seront disponibles sur le site Web de Pharvaris. L'entreprise fera également un don au programme de bourses Marcus Maurer à travers GA2LEN en mémoire du Professeur Marcus Maurer.
Pharvaris (Nasdaq: PHVS), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, kündigte die Annahme von sechs Abstracts für die Präsentation beim Global Angioedema Forum 2024 – HAEi Global Leadership Workshop in Kopenhagen an. Die Präsentationen konzentrieren sich auf deucrictibant, einen oralen Bradykinin B2-Rezeptor-Antagonisten zur Behandlung von hereditärem Angioödem (HAE) Attacken. Zwei mündliche Präsentationen und vier Posterpräsentationen werden Themen abdecken, darunter:
1. Langfristige Sicherheit und Wirksamkeit von deucrictibant zur HAE-Prophylaxe
2. Langfristige Wirksamkeit und Sicherheit bei der Behandlung von HAE-Attacken
3. Ergebnisse der CHAPTER-1 Phase 2 Studie
4. Auswirkungen auf die gesundheitsbezogene Lebensqualität
5. Vergleich mit Standardbehandlungen
6. Design der RAPIDe-3 Phase 3 Studie
Die Präsentationsmaterialien werden auf der Website von Pharvaris zur Verfügung stehen. Das Unternehmen wird auch eine Spende an das Marcus Maurer Fellowship Programm über GA2LEN in Erinnerung an Prof. Marcus Maurer machen.
- Acceptance of six abstracts for presentation at a major industry event
- Two oral presentations and four poster presentations showcasing deucrictibant's potential
- Long-term safety and efficacy data available for both prophylaxis and treatment of HAE attacks
- Positive impact on health-related quality of life reported for deucrictibant
- Ongoing Phase 3 trial (RAPIDe-3) for deucrictibant in treating HAE attacks
- None.
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows:
- Title: Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Presenter: Marc A. Reidel, M.D., M.S.
Format: Oral and Poster
Date, time: Oral: Saturday, Oct. 5, Session 5, 9:59 CEST (3:59 a.m. EDT) | Poster: Friday, Oct. 4, 18:00-18:30 CEST (12:00-12:30 p.m. EDT), Poster Walk 1 - Title: Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Presenter: Anna Valerieva, M.D., Ph.D.
Format: Oral and Poster
Date, time: Oral: Saturday, Oct. 5, Session 5, 10:08 CEST (4:08 a.m. EDT) | Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 4 - Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Emel Aygören-Pursun, M.D.
Format: Poster
Date, time: Friday, Oct. 4, 18:00-18:30 CEST (12:00-12:30 p.m. EDT), Poster Walk 3 - Title: Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster
Date, time: Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 2 - Title: Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema
Presenter: Danny M. Cohn, M.D., Ph.D.
Format: Poster
Date, time: Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 2 - Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Presenter: Phillip H. Li, MBBS, FRCP
Format: Poster
Date, time: Friday, Oct. 4, 18:00-19:00 CEST (12:00-1:00 p.m. EDT), Poster Walk 1
The presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.
In memory of Prof. Marcus Maurer, Professor of Dermatology and Allergy, Executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin, and Co-Director of Allergology and Immunology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Pharvaris will make a donation to the Marcus Maurer Fellowship Program through GA2LEN, the Global Allergy and Asthma Excellence Network.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.
FAQ
What is the main focus of Pharvaris' presentations at the 2024 HAEi Global Leadership Workshop?
How many abstracts will Pharvaris (PHVS) present at the 2024 HAEi Global Leadership Workshop?
What are the key studies of deucrictibant that Pharvaris (PHVS) will present data from?
When and where will the 2024 HAEi Global Leadership Workshop take place?
